NCT07182838View on ClinicalTrials.gov

Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 12, 2025

Primary Completion Date

August 18, 2026

Study Completion Date

October 28, 2026

Conditions
HIV Infections
Interventions
BIOLOGICAL

HIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous use

"* By the percutaneous route with the multiple puncture device~* HIV GP160 0.1 mg x 1 mL plus BCG Organism 50 MG Mix"

Trial Locations (1)

20853

Medicine Invention Design Incorporation - IORG0007849 - NPI 1023387701, Rockville

All Listed Sponsors
collaborator

UnitedHealthcare

OTHER

lead

Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair

INDUSTRY